Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL27647104 | 0.94 | PLA2G1B (0.41) | PLA2G1BPLA2G2ATSHRTHRBALDH1A1 | |
| Hexane SCHEMBL120948 | 0.87 | TSHR (0.54) | PLA2G1BPLA2G2ATSHRTHRBALDH1A1 | |
| Hexane SCHEMBL9422173 | 0.87 | TSHR (0.54) | PLA2G1BPLA2G2ATSHRTHRBALDH1A1 | |
| Chloroform SCHEMBL378302 | 0.87 | LMNA (0.33) | LMNA | |
| Hexane SCHEMBL1193584 | 0.84 | TSHR (0.47) | PLA2G1BPLA2G2ATSHRTHRBALDH1A1 | |
| SCHEMBL27275484 | 0.84 | PLA2G1B (0.48) | PLA2G1BPLA2G2ATSHRTHRBLMNA | |
| Octane SCHEMBL639987 | 0.83 | TSHR (0.61) | PLA2G1BPLA2G2ATSHRTHRBALDH1A1 | |
| Chloroform SCHEMBL7930106 | 0.83 | LMNA (0.31) | LMNA | |
| Tetradecane SCHEMBL28338948 | 0.83 | TSHR (0.61) | PLA2G1BPLA2G2ATSHRTHRBALDH1A1 | |
| SCHEMBL28521976 | 0.83 | TSHR (0.61) | PLA2G1BPLA2G2ATSHRTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| EP-2062895-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-20050154199-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2005-07-14 | — | — | US | disclosed |
| EP-1212096-A2 | DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME | Brenner, Sydney (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001013958-A2 | DRUG CONJUGATES AND METHODS OF DESIGNING THE SAME | BRENNER SYDNEY (US) | 2001-03-01 | — | — | WO | disclosed |
| EP-0797579-B1 | ERYTHROMYCIN A 9-0-OXIME DERIVATIVES ENDOWED WITH ANTIBIOTIC ACTIVITY | ZAMBON SPA (IT) | 2000-03-15 | — | — | EP | disclosed |
| US-5847092-A | Erythromycin A 9-0 oxime derivatives endowed with antibiotic activity | ZAMBON GROUP S.P.A. (IT) | 1998-12-08 | — | — | US | disclosed |
| US-5643896-A | TREATMENT OF MENOPAUSE SYMPTOMS, OSTEOPOROSIS, CARDIOVASCULAR DISORDERS OR ESTROGEN DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996026935-A1 | 2-BENZYL-3-ARYLBENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1996-09-06 | — | — | WO | disclosed |
| EP-0729955-A1 | 2-Benzyl-3-Arylbenzothiophenes useful for the treatment of post-menopausal syndrome | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5552401-A | CARDIOVASCULAR DISORDERS, OSTEOPOROSIS AND ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5354861-A | Binds to antiestrogen binding sites; antiproliferative activity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1994-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154199-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | PLA2G1B 3681/4885PLA2G2A 3477/4885TSHR 4746/4885 |
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ABCG2, HTR3C, AADAC | PLA2G1B 2084/4885PLA2G2A 2681/4885TSHR 713/4885 |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | PLA2G1B 3550/4885PLA2G2A 3356/4885TSHR 4727/4885 |
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | PLA2G1B 3681/4885PLA2G2A 3477/4885TSHR 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.